Side effects and perceptions following Sinopharm COVID-19 vaccination

Saeed, Balsam Qubais; Al-Shahrabi, Rula; Alhaj, Shaikha Salah; Alkokhardi, Zainab Mansour; Adrees, Ahmed Omar

doi:10.1016/j.ijid.2021.08.013

Cited by 196 publications

(214 citation statements)

References 29 publications

Supporting

Mentioning

167

Contrasting

Unclassified

Order By: Relevance

“…Comparable common side effects were reported during clinical trials in China [10,11]. Side effects after the Sinopharm vaccine, from clinical trials and real-world practice, were comparable to that of other vaccines [12,13]. Common side effects reported from Saudi Arabia, due to Pfizer -BioNTech COVID-19 vaccines, were in line with what was mentioned above.…”

Section: Introductionsupporting

confidence: 78%

“…Comparably, Baden et al observed that the side effects after the Moderna vaccine were more frequent in the 18 to <65 years old group than the ≥65 years old group [24]. In real-world practice, the Sinopharm vaccine showed side effects that were more frequent in ≤ 49-year-old [13]. Generally, side effects represent a major determinant of vaccination acceptance.…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Side effects following COVID-19 vaccination: A cross-sectional survey with age-related outcomes in Saudi Arabia

Alghamdi¹,

Ibrahim²,

Alraey³

et al. 2021

J Adv Pharm Educ Res

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 78%

Section: Introductionmentioning

confidence: 96%

Side effects following COVID-19 vaccination: A cross-sectional survey with age-related outcomes in Saudi Arabia

Alghamdi¹,

Ibrahim²,

Alraey³

et al. 2021

J Adv Pharm Educ Res

View full text Add to dashboard Cite

show abstract

“…Animal experiments and phase 1 and 2 clinical trials have consistently demonstrated that inactivated SARS-CoV-2 vaccines had notable immunogenicity and a low rate of adverse reactions [9]. A recent cross-sectional study showed side effects of the Sinopharm COVID-19 vaccination for the first and second doses were mild and predictable, and there were no hospitalization cases [10].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series

Ruan

Tang

et al. 2021

Vaccines

View full text Add to dashboard Cite

In this study, we report the safety of coronavirus disease 2019 (COVID-19) vaccine in patients with myasthenia gravis (MG). Patients who were vaccinated against COVID-19 were included. Demographics, clinical characteristics, medications, and vaccination information were collected. The main observation outcome is the worsening of MG symptoms within 4 weeks following COVID-19 vaccination. A total of 22 patients with MG vaccinated for COVID-19 were included. Ten (45.5%) patients had ocular MG (OMG), and 12 (55.5%) patients had generalized MG (GMG). Six (27.3%) patients were female, and the mean (SD) onset age was 45.4 (11.8) years. Nineteen (86.4%) patients were seropositive for acetylcholine receptors (AChR) antibody. Seven (31.8%) patients underwent thymectomy, and four of them confirmed thymoma pathologically. Twenty-one patients were administrated with inactivated vaccines, and the remaining one was administrated with recombinant subunit vaccine. Twenty (90.9%) patients did not present MG symptom worsening within 4 weeks of COVID-19 vaccination, and two (9.1%) patients reported slight symptom worsening but resolved quickly within a few days. Our findings suggest inactivated COVID-19 vaccines might be safe in MG patients with Myasthenia Gravis Foundation of America (MGFA) classification I to II, supporting the recommendation to promote vaccination for MG patients during the still expanding COVID-19 pandemic.

show abstract

“…There is little published data to corroborate adverse responses to the COVID-19 vaccination. Only a few studies discuss the side effects of the Sinopharm vaccines [15,18,[23][24][25]. The most common adverse effects of Sinopharm vaccination, according to these studies, were weariness, injection site pain, headache, fever, lethargy, chills, and myalgia.…”

Section: Introductionmentioning

confidence: 99%

Unfolding the Mild to Moderate Short-Term Side Effects of Four COVID-19 Vaccines Used in Bahrain: A Cross-Sectional Study

Zahid

2021

Vaccines

View full text Add to dashboard Cite

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) created a global pandemic (COVID-19) that has resulted in massive health and economic losses. The current unavailability of treatments leaves vaccination as the only way to control this disease. There are four vaccines (Sinopharm, Pfizer—BioNTech, Sputnik, and AstraZeneca) available in Bahrain. This project aimed to study the most common side effects resulting from the first and second doses of these four vaccines. Data were collected through an online questionnaire answered by 311 individuals who received both doses of one of these four vaccines. The results of this study revealed that regardless of the vaccine identity, participants experienced more side effects from the second dose. Among the different side effects, pain at the site of injection was primarily observed after the first dose of the Pfizer vaccine (43%), which was followed by the AstraZeneca vaccine (31%). Moreover, fever was observed in participants after the first dose of the Sputnik vaccine (37%), while headache was mainly observed after the first dose of the Pfizer vaccine (32%). It is important to note that fatigue was observed after the first dose of all four vaccines but was reported by the highest proportion of respondents in the Pfizer group (28%). Interestingly, there are some side effects, such as pain at the site of injection, that are correlated with fever (r = 0.909). Similarly, headache is correlated with fever (r = 0.801) and pain at the site of injection (r = 0.868). Overall, it was observed that recipients of the Sinopharm vaccine reported the mildest side effects among all four vaccines. The crucial finding of this study is that the first and second dosage post-vaccination side effects were modest and predictable with no occurrences of hospitalization; this information can assist in lessening vaccine apprehension.

show abstract

Side effects and perceptions following Sinopharm COVID-19 vaccination

Cited by 196 publications

References 29 publications

Side effects following COVID-19 vaccination: A cross-sectional survey with age-related outcomes in Saudi Arabia

Side effects following COVID-19 vaccination: A cross-sectional survey with age-related outcomes in Saudi Arabia

COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series

Unfolding the Mild to Moderate Short-Term Side Effects of Four COVID-19 Vaccines Used in Bahrain: A Cross-Sectional Study

Contact Info

Product

Resources

About